ArchivesMagazine - 17 Dec 2020Why aren’t investors cheering AstraZeneca’s bid for Alexion? The market has questioned the strategic logic and whether a bidding war could emerge 17 December 2020|News|by Martin Gamble Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email < Marketing of high-risk mini-bonds banned from 2021 Earnings expectations are rising for FTSE 100 bottler Coca-Cola HBC > Issue: 17 Dec 2020 - Page 8 | Contents Next: Earnings expectations are rising for FTSE 100 bottler Coca-Cola HBC Previous: Marketing of high-risk mini-bonds banned from 2021 Find out how to deal online from £1.50 in a SIPP, ISA or Dealing account. Share on Facebook Share on Bluesky Share on X (Twitter) Share by Email Martin Gamble Issue Contents Ask Tom Why shouldn’t I opt out of my workplace pension? Book reviews This book can help you avoid potential stock disasters Editor's View Don’t expect a return to normal for bank dividends just yet Feature Investment outlook: 10 big questions for 2021 Is there any value in bonds going into 2021? First-time Investor How to navigate an annual report (and why it is full of great information) Great Ideas Buy into the structurally-driven Ideagen growth story Earnings expectations are rising for FTSE 100 bottler Coca-Cola HBC GlaxoSmithKline vaccine delay and Novacyt’s new virus strain test Inditex keeps the tills ringing in run-up to Christmas More upgrades from trusty consumer favourite UPGS Investment Trusts Best performing investment trusts in 2020 News Disney shares hit new record high on plans for major TV and film push Surge in Airbnb and DoorDash stock renews tech bubble debate Why aren’t investors cheering AstraZeneca’s bid for Alexion? Iron ore trumps gold as the hot commodity of 2020 Marketing of high-risk mini-bonds banned from 2021 Aberdeen Standard snares Tritax as logistics property boom continues Personal Finance The big changes for personal finance in 2021 Russ Mould The outlook for FTSE 100 dividends in 2021
